Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Transcript
Given the findings of DESTINY-Breast04, how can we better evaluate HER2 status to make treatment of HER2-low actionable and accurate?
I think that we need to make sure that we're capturing the HER2-low population. What DESTINY-Breast04 showed us is that among HER2-low patient populations with advanced breast cancer, there's a survival benefit from being treated with trastuzumab deruxtecan in comparison to chemotherapy. So, we need to make sure that we're identifying this HER2-low patient population.
It comprises about 55% of our advanced breast cancer patients. And we need to make sure that IHC [immunohistochemistry] is being done by pathology. Also, IHC is a little bit tricky and can have interoperator variability. So, we need to make sure that we work with our pathologists to identify those that are IHC1+, IHC2+ and FISH [fluorescence in situ hybridization]-negative. This means working closely with our pathologist to identify this patient population.
Also, in patients with advanced breast cancer who frequently have metastatic disease to the bone and may have bone biopsies that undergo decalcification, we need to recognize some of the limitations of that decalcification process on the sensitivity of HER2 evaluation and think about how we investigate each and every patient for what they might benefit from.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More